Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Policy

Chemistry Journals Burgeon

Publishing: Both ACS and RSC will establish new journals in 2010

by Sophie L. Rovner
November 23, 2009 | A version of this story appeared in Volume 87, Issue 47

[+]Enlarge
Credit: Jon Rou/Emory U
Liotta will be the editor in chief of ACS Medicinal Chemistry Letters.
Credit: Jon Rou/Emory U
Liotta will be the editor in chief of ACS Medicinal Chemistry Letters.

Readers and authors will have several new peer-reviewed chemistry journals to peruse next year.

The American Chemical Society will begin publishing ACS Medicinal Chemistry Letters in January. The society has appointed Dennis C. Liotta, an organic chemistry professor at Emory University and director of the Emory Institute for Drug Discovery, as editor in chief.

ACS Medicinal Chemistry Letters will publish experimental and theoretical results in pure and applied medicinal chemistry on topics including discovery and design, biological evaluation, delivery, and pharmacology. It will include sections describing significant new patents and drug discovery tools.

The online-only journal will serve as a companion to ACS’s Journal of Medicinal Chemistry, which will subsequently concentrate on full articles and reviews.

“We want to make ACS Medicinal Chemistry Letters the premier journal for communicating high-quality results in medicinal chemistry and related fields,” Liotta says.

Liotta’s “broad background in drug discovery gives him a unique opportunity to attract high-quality medicinal chemistry contributions to the new journal,” says William J. Greenlee, a medicinal chemist at Merck Research Laboratories in Kenilworth, N.J., and editor of the Journal of Medicinal Chemistry’s Perspectives section.

Liotta, whose research focuses on the discovery and development of anticancer, anti-inflammatory, and antiviral therapeutic agents, “is well-known for his impressive accomplishments in academia, as an industry consultant and company founder, and as the inventor of two major FDA-approved drugs for treatment of HIV infection,” Greenlee says.

Liotta earned a B.A. in chemistry at Queens College in 1970 and a Ph.D. in organic chemistry at the City University of New York in 1974. After a postdoctoral fellowship at Ohio State University, he joined Emory in 1976 as an assistant professor and was promoted to full professor in 1988.

Also this coming January, ACS will publish the first issues of the Journal of Physical Chemistry Letters and ACS Chemical Neuroscience (C&EN, May 25, page 34, and June 29, page 9). ASAP articles from the journals are already available online. The society will begin copublishing the Journal of Chemical Education with the ACS Division of Chemical Education that same month (C&EN, Oct. 19, page 10).

On the other side of the Atlantic, the Royal Society of Chemistry (RSC) will launch three monthly chemistry journals. Polymer Chemistry will publish communications, reviews, and full papers on synthetic and biological macromolecules starting early next year. The society’s MedChemComm will debut in mid-2010 and will focus on medicinal chemistry research in concise research and review articles.

Also in midyear, RSC will introduce Chemical Science, which it says will publish “findings of exceptional significance from across the chemical sciences.” RSC notes that the journal will complement its flagship Chemical Communications and Chemical Society Reviews journals and will allow authors to present “accounts of their novel research without page restrictions.”

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.